COO Dr Nigel Stevenson participated in a 90 minute CME event at the 2017 SNMMI Annual Meeting. In the CME event CE98, “Targeting radionuclide therapy in various non-malignant arthrititc conditions using radiosynoviorthesis (RSO),” he educated the audience on the  available RSO isotopes, and also on tin-117m manufacturing an dcharacteristics. Other participants in the CME event included Dr Knute Liepe who discussed the global RSO experience, Dr Jimmy Lattimer who described the current canine tin-117m elbow OA trial, and Dr Philip Cohen who discussed an ongoing Canadian trial using other isotopes to treat OA. The event was moderated by Dr Suresh Srivastava.